CTLA4 and neoplasm: Although results were encouraging in the phase II HAWK trial of durvalumab in R/M HNSCC10 and other phase I/II studies involving anti-PD-(L)1 and anti-CTLA-4 combinations in various tumor types,14,17, 18, 19 our study showed limited clinical benefit with durvalumab plus tremelimumab.